INFO60
SpotlightTopics60sNEWQuizLogin
IndiaAI & TechBusinessTechnologySportsEntertainmentHealthScienceWorld
INFO60

Know more. Read less. What matters, fast.

Company

  • About
  • Contact
  • Editorial Policy
  • Corrections
  • Our desks
  • Publishers

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Account

  • Delete Account
  • Spotlight
  • Quick Cards
  • Topics
  • Web Stories
  • Hindi News

Free. One email a day. Unsubscribe anytime.

Editions

  • India
  • United States
  • United Kingdom
  • Canada
  • Australia
  • UAE & Gulf
  • Singapore
  • Hindi
  • All countries
© 2026 Info60. All rights reserved.
Home›science›Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
science

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

By Info60 World Desk•Summary of reporting by Businesswire•Sep 23, 2026•0 views•
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the
ONLY AVAILABLE IN PAID PLANS
Read Full Article

Share this story

Report an error

Up next

Related Stories

Autonomous Mobile Robots Market Forecasts Growth from $2.39B (2025) to $7.07B by 2032, Profiling Locus Robotics, Omron, Mobile Industrial Robots, Fetch Robotics & Geek+

Globenewswire_fr

Automotive Lead-Acid Battery Market Forecasts Growth from $31.08B (2026) to $37.45B by 2033, Profiling Clarios, Exide, GS Yuasa, East Penn & EnerSys

Globenewswire_fr

Quality Management System Software Market Forecasts Growth from $11.73B (2026) to $20.43B by 2031, Profiling Veeva Systems, Siemens, PTC, SAP, Oracle & 15 Others

Globenewswire_fr

Event Management Software Market Forecasts Growth from $18.6B (2026) to $36.8B by 2031, Profiling Cvent, Eventbrite, Zoom, Bizzabo, RingCentral & Others

Globenewswire_fr

Medical Equipment Cooling Market Forecasts Growth from $0.63B (2026) to $0.82B by 2031, Profiling Parker Hannifin, Daikin, Thermo Fisher & Boyd Corporation

Globenewswire_fr

Comments (0)

Please login to comment

Login
💬

No comments yet. Be the first to comment!